• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by NeOnc Technologies Holdings Inc.

    4/25/25 3:56:55 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTHI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    NEONC TECHNOLOGIES HOLDINGS, INC.

    (Name of Issuer)


    COMMON STOCK, par value $0.0001 per share

    (Title of Class of Securities)


    64051A101

    (CUSIP Number)


    Dr. Thomas Chen
    23975 Park Sorrento, Suite 205
    Calabasas, CA, 91302
    310 663 7831

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    03/26/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    64051A101


    1 Name of reporting person

    Amir F. Heshmatpour
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    6,213,499.00
    8Shared Voting Power

    275,000.00
    9Sole Dispositive Power

    6,213,499.00
    10Shared Dispositive Power

    275,000.00
    11Aggregate amount beneficially owned by each reporting person

    6,488,499.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox checked
    13Percent of class represented by amount in Row (11)

    34.3 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    (1) Aggregate amount owned includes 275,000 shares held by Reporting Person's minor daughter, 3,714,020 shares of common stock held by AFH Holding & Advisory, LLC of which Reporting Person is the sole member, and 1,024,479 shares of common stock held by HCWG LLC of which Reporting Person holds 25% of the membership interests and is the managing member.


    SCHEDULE 13D

    CUSIP No.
    64051A101


    1 Name of reporting person

    AFH Holding & Advisory, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    3,714,020.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    3,714,020.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    3,714,020.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    19.64 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    64051A101


    1 Name of reporting person

    HCWG LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    1,024,479.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    1,024,479.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    1,024,479.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.42 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    COMMON STOCK, par value $0.0001 per share
    (b)Name of Issuer:

    NEONC TECHNOLOGIES HOLDINGS, INC.
    (c)Address of Issuer's Principal Executive Offices:

    23975 Park Sorrento, Suite 205, Calabasas, CALIFORNIA , 91302.
    Item 1 Comment:
    This Schedule 13D relates to the common stock, par value $0.0001 per share (the "Common Stock"), of NeOnc Technologies Holdings, Inc. ("Issuer" or "NeOnc"). Following the direct listing of Issuer's Common Stock on the Nasdaq Global Market, issued and outstanding Common Stock totaled 18,908,025 shares.
    Item 2.Identity and Background
    (a)
    This Schedule 13D is filed on behalf of Amir. F. Heshmatpour, AFH Holding & Advisory, LLC ("AFH Holding") and HCWG LLC ("HCWG"), who are collectively referred to herein as "Reporting Persons".
    (b)
    The address of each Reporting Person is 23975 Park Sorrento, Suite 205, Calabasas, CA 91302.
    (c)
    Amir F. Heshmatpour is the sole member of AFH Holding and the managing member of HCWG. AFH Holding is a family office and holding company. HCWG is a Delaware limited liability company.
    (d)
    During the last five years, no Reporting Person has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    Within the last five years, no Reporting Person has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction nor been subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Amir F. Heshmatpour is a citizen of the United States. Each of AFH Holding and HCWG is a Delaware limited liability company.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Exercise of warrant held by HCWG. See also Item 4 below.
    Item 4.Purpose of Transaction
     
    In connection with Issuer's direct listing on the Nasdaq Global Market on March 26, 2025, HCWG transacted a cashless exercise of a warrant issued by the Company for 312,500 shares of common stock. The exercise price of the warrant was $12 per share and the cashless withholding of shares was executed at $25 per share resulting in withholding of 162,500 shares and acquisition of 150,000 shares of common stock in the transaction.
    Item 5.Interest in Securities of the Issuer
    (a)
    See Item 11 of the cover page for each Reporting Person.
    (b)
    See Items 7 and 9 of the cover page for each Reporting Person.
    (c)
    See Item 4 above.
    (d)
    See Item 4 above.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    None.
    Item 7.Material to be Filed as Exhibits.
     
    Not applicable.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Amir F. Heshmatpour
     
    Signature:/s/ Amir F. Heshmatpour
    Name/Title:Amir F. Heshmatpour
    Date:04/25/2025
     
    AFH Holding & Advisory, LLC
     
    Signature:/s/ Amir F. Heshmatpour, Member
    Name/Title:Amir F. Heshmatpour, Member
    Date:04/25/2025
     
    HCWG LLC
     
    Signature:/s/ Amir F. Heshmatpour, Managing Member
    Name/Title:Amir F. Heshmatpour, Managing Member
    Date:04/25/2025
    Get the next $NTHI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTHI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NTHI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

      -- 176 Patents Issued and Outstanding Reinforces NeOnc's Competitive Position -- CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, reinforcing its competitive position. The Company's IP portfolio, covering its core pipeline, currently comprises 126 issued patents - 29 in the United States and 97 internationally; and 50 pending patents - 19 in the United States and 31 internationally. NeOnc's expanding IP portfolio reflects its innovation engine as well as its comm

      4/15/25 8:05:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

      -- Trial Read-Out Data Expected in Early 2026 -- CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, NEO100-01 in September. Only six patients remain to complete the trial's 25-patient enrollment target. This landmark trial, for which read-out data is expected in early 2026, investigates NEO100, a proprietary, highly purified version of perillyl alcohol, delivered intranasally, a non-invasive me

      4/14/25 8:05:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

      CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company. Heshmatpour will retain his role as Executive Chairman, while taking on day-to-day leadership responsibilities to accelerate the Company's strategic and clinical initiatives. "Amir's appointment as President reflects our commitment to strong, visionary leadership as NeOnc advances its clinical programs," said Dr. Thomas Chen, CEO of NeOnc. "His e

      4/10/25 8:05:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Garnett Keithly bought $976 worth of shares (135 units at $7.23), increasing direct ownership by 0.06% to 240,225 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/22/25 5:55:49 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CFO Garnett Keithly bought $631 worth of shares (90 units at $7.01), increasing direct ownership by 0.04% to 240,090 units (SEC Form 4)

      4/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/22/25 5:54:01 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Delshad Jim bought $37,258 worth of shares (5,100 units at $7.31), increasing direct ownership by 10% to 55,310 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/19/25 9:27:02 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    SEC Filings

    See more
    • SEC Form 10-Q filed by NeOnc Technologies Holdings Inc.

      10-Q - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

      5/9/25 5:00:30 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by NeOnc Technologies Holdings Inc.

      EFFECT - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

      5/7/25 12:15:13 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by NeOnc Technologies Holdings Inc.

      424B5 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

      5/6/25 5:07:31 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Garnett Keithly bought $976 worth of shares (135 units at $7.23), increasing direct ownership by 0.06% to 240,225 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/22/25 5:55:49 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CFO Garnett Keithly bought $631 worth of shares (90 units at $7.01), increasing direct ownership by 0.04% to 240,090 units (SEC Form 4)

      4/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/22/25 5:54:01 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Delshad Jim bought $37,258 worth of shares (5,100 units at $7.31), increasing direct ownership by 10% to 55,310 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/19/25 9:27:02 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care